EKEnes Mustafa Kaya

Enes Mustafa Kaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Enes Mustafa Kaya has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy

    by Halim Özçevik, Enes Mustafa Kaya, Burcu Esen Akkaş, Gündüzalp Buğrahan Babacan, Ayşe Betül Dere, Berke Güner, Hatice Pekediş, Cengiz Yağmur, Meryem Kaya

    Background/Objectives: Current guidelines define no absolute contraindication to prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), yet some patients receive only a single cycle. We aimed to characterize this single-cycle attrition (SCA) and derive an exploratory pretreatment risk score predicting it. Methods: Seventy consecutive patients with metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA RLT at one center (2022–2025) were reviewed; 58 were assessable. SCA was defined as permanent non-initiation of a second cycle. The analyses employed false-discovery-rate-adjusted nonparametric comparisons, receiver operating characteristic (ROC), Kaplan–Meier and univariable Cox methods, with optimism-corrected bootstrap internal validation. Results: SCA occurred in 12 of 58 patients (20.7%), owing to death or rapid clinical deterioration (n = 8) or grade 3–4 hematotoxicity (n = 4); all 12 died (median overall survival 3 months). Higher C-reactive protein (CRP), lower lymphocytes and hemoglobin, and higher alkaline phosphatase (ALP) and prostate-specific antigen (PSA) separated the groups (all q < 0.05). The five-item Single-Cycle Attrition Risk (SCAR-5) score (one point each: CRP ≥ 16.5 mg/L, lymphocytes ≤ 1.39 × 109/L, hemoglobin ≤ 9.6 g/dL, ALP ≥ 191 U/L, PSA ≥ 34.2 ng/mL) discriminated SCA with an optimism-corrected area under the ROC curve (AUC) of 0.88 (apparent AUC 0.95, 95% confidence interval (CI) 0.89–0.99). No SCA occurred below score 3 (0/39; upper 95% confidence limit 9.0%); a score ≥ 3 identified all events (sensitivity 100%, 95% CI 74–100; specificity 85%, 95% CI 71–94) and was associated with shorter survival (univariable Cox hazard ratio 3.94, 95% CI 2.01–7.74). Conclusions: One in five patients who initiated RLT did not proceed beyond the first cycle. SCAR-5, an exploratory score derived from routine pretreatment laboratory values, stratified risk of early treatment attrition; external prospective validation is required before clinical use.

  • Glass versus resin microspheres in ⁹⁰Y radioembolization for hepatocellular carcinoma: toxicity patterns under uniform voxel-based dosimetry

    by Ali Dablan, Enes Mustafa Kaya, Meryem Kaya, Emrah Birol, Çağrı Erdim, Mustafa Fatih Arslan, Mehmet Cingöz, Oğuzhan Türksayar, Cihan Şin, Halil Burak Kapucu, et al.

  • Is early imaging a pitfall? Effect of [⁶⁸Ga]Ga-PSMA PET/CT timing after biopsy on SUVmax and adverse pathology prediction in low-to-intermediate risk prostate cancer

    by Enes Mustafa Kaya, Burcu Esen Akkaş, Mehmetcan Uluçay, Fuad Aghazada, Halil Lütfi Canat, Harun Özdemir, Merve Şam Özdemir, Nilsen Yıldırım Erdoğan, Meryem Kaya

  • Elevated baseline C-reactive protein is associated with treatment failure and shorter survival after Yttrium-90 radioembolization in hepatocellular carcinoma

    by Enes Mustafa Kaya, Burcu Esen Akkaş, Tevfik Güzelbey, Çağrı Erdim, Mustafa Fatih Arslan, Cihan Şin, Halil Burak Kapucu, Ayşe Betül Dere, Meryem Kaya

    Objective To evaluate the impact of baseline C-reactive protein (CRP) on outcomes after yttrium-90 (Y-90) radioembolization (RE) for hepatocellular carcinoma (HCC). Methods This retrospective study included patients with HCC treated with Y-90 RE at a tertiary center (June 2022–June 2025). Dosimetry was based on 99mTc-MAA SPECT/CT with refined post hoc high-dose definitions. High-dose therapy was defined as tumor-absorbed dose > 250 Gy for lobar treatments (glass or resin). For segmentectomy, high dose was defined as perfused-liver absorbed dose > 400 Gy for glass and > 250 Gy for resin microspheres. Patients were stratified by baseline CRP: low (≤ 1 mg/dL) vs. high (> 1 mg/dL). Tumor response was assessed on gadoxetate-enhanced MRI using mRECIST. Local progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were estimated by Kaplan–Meier and compared with log-rank tests. Cox regression identified independent prognostic factors. Results The cohort comprised 103 patients (mean age 65.8 ± 9 years; 76.7% male). BCLC stages were A (n = 27), B (n = 35), and C (n = 41); median largest tumor diameter was 6.0 cm (IQR 4.1–8.8), and median follow-up was 26 months. On multivariable analysis, CRP > 1 mg/dL independently predicted inferior LPFS (HR 3.6, p < 0.001), PFS (HR 2.7, p = 0.002), and OS (HR 4.8, p < 0.001). High-dose treatment was independently associated with improved LPFS (HR 0.55, p = 0.043) and OS (HR 0.47, p = 0.021). In subgroup analyses, high-dose treatment was associated with longer survival in the low-CRP group but not in the high-CRP group. Conclusion Baseline CRP > 1 mg/dL is a strong adverse prognostic factor after Y-90 RE. High-dose RE was associated with longer survival in patients with low CRP but not in those with elevated CRP; this hypothesis-generating observation requires prospective confirmation.


  • Open Access

    Is 400 Gy enough for every tumor? The 3 cm cutoff and a modified BCLC classification for predicting complete response after radiation segmentectomy in hepatocellular carcinoma

    by Enes Mustafa Kaya, Burcu Esen Akkaş, Çağrı Erdim, Ali Dablan, Mustafa Fatih Arslan, Cihan Şin, Halil Burak Kapucu, Ayşe Betül Dere, Meryem Kaya

  • Physiological differences in bone uptake of [99mTc]Tc-pyrophosphate in men and women undergoing cardiac scintigraphy

    by Elife Akgün, Göksel Alçın, Ömer Faruk Şahin, Dilruba Şahin, Mustafa Enes Kaya, Selin Gül Yaran, Cihan Şin, Özge Vural Topuz, Burcu Esen Akkaş, Meryem Kaya, et al.


  • Correlation between the clinical features of patients with spina bifida and the findings of DMSA scintigraphy

    by Seyma Omay, Sevgi Yavuz, Burcu E. Akkas, Özgür Omak, Meryem Kaya, Enes M. Kaya

    Objective In patients with spina bifida (SB), even if kidney function is normal at birth, the risk of developing chronic kidney failure later in life is high due to neurogenic deficits that impair bladder emptying as the child grows. The aim of this study is to investigate the correlation between neurological deficits and structural anomalies, which dominate the clinical presentation in children with spina bifida, and renal cortical function using Tc99m-labeled DMSA (Dimercaptosuccinic acid) scintigraphy. Methodology 206 pediatric cases (100M, 106 F; age 0-18 years, mean:7.2) with SB who underwent DMSA scintigraphy for recurrent urinary tract infections (RUI) were included in this retrospective study. In 78 cases SPECT/CT (Single Photon Emission Computed Tomography) was used for demarcation of the anatomical structures. clinical findings, renal functions, structural and neurological anomalies of the patients, the history of urinary tract surgery, the frequence of RUI and vesicoureteral reflux (VUR), the frequency of Clean Intermittent Catheterization (CIC), prophylactic antibiotic use, hypertension, proteinuria, ultrasound findings and serum urea-creatinine levels. The patients were grouped according to the severity of neurological deficits. DMSA scintigraphy findings were compared with the clinical data and the severity of ND. Findings Among 206 patients with SB, 126 had severe neurogenic dysfunction (ND), 41 had moderate ND, and 39 had no ND. A total of 117 children presented with complicated meningomyelocele at birth and underwent surgical repair. Ventriculoperitoneal shunt implantation was performed in 104 cases, while 2 had cervical SB and 1 had thoracolumbar SB. Neurogenic bladder was identified in 199 patients. Clean intermittent catheterization (CIC) was performed by 156 patients, and 134 received prophylactic antibiotic therapy. Unilateral renal agenesis was detected in 8 cases, and horseshoe kidney anomaly in 5 cases. When kidneys were evaluated separately, among a total of 404 renal units, stage ≥3 hydronephrosis was observed in 38 units, and stage ≥2 VUR was detected in 73 units on voiding cystourethrograms (VCUG). Ultrasound revealed structural renal dysmorphism in 176 renal units. The incidence of ≥stage 2 VUR on VCUG was significantly higher in children with dysmorphic kidneys compared to those without dysmorphism (26% vs. 13%, p = 0.01). A significant positive correlation was found between structural renal dysmorphism and cortical defects on DMSA scintigraphy. Cortical defects were detected in 74% of patients with dysmorphic kidneys, compared with 21% of those without ( p = 0.001). DMSA scans showed cortical damage in 66% (44 renal units) with ≥stage 3 VUR and in 38% (128 renal units) with stage ≤2 VUR on VCUG. Overall, cortical defects consistent with renal scarring were observed in 174 renal units on DMSA scintigraphy. The presence of renal cortical damage was significantly associated with the severity of ND. The rate of cortical damage was 52% in children with severe ND, 39% in those with moderate ND, and 28% in patients without ND (p = 0.008). In 78 children who underwent SPECT/CT imaging, planar DMSA images from 11 children were re-evaluated using anatomical correlation data. CT was performed as a low-dose anatomical correction procedure. Conclusion This study demonstrated that renal scarring and cortical loss are common in children with spina bifida. Renal dysmorphism, vesicoureteral reflux, and neurogenic bladder contribute significantly to renal parenchymal injury. Furthermore, the severity of neurogenic dysfunction correlates with the extent of cortical loss. DMSA scintigraphy remains a reliable, non-invasive modality for the assessment of renal cortical function in children with SB. What is Known: • Cortical loss in the kidneys increases mortality and morbidity in patients with spina bifida. • DMSA scintigraphy is highly valuable in demonstrating cortical function. What is New: • Over the past three decades, patients with spina bifida have achieved longer life expectancy due to advances in medical care. • Contrary to common belief, DMSA scintigraphy still plays an effective role in the follow-up and management of this patient group for the preservation of renal function. It remains valuable in assessing and preserving cortical function in adult patients with spina bifida.